Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET
|
Protara Therapeutics
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
November 12, 2024 08:00 ET
|
Protara Therapeutics
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in...
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 06, 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
October 21, 2024 08:00 ET
|
Protara Therapeutics
Remain on track to initiate registrational THRIVE-3 trial in 1Q’ 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing...
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 09, 2024 08:05 ET
|
Protara Therapeutics
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE...
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
September 09, 2024 08:00 ET
|
Protara Therapeutics
78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injuryIV Choline...
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 06, 2024 08:00 ET
|
Protara Therapeutics
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1...
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 24, 2024 17:06 ET
|
Protara Therapeutics
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 21, 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...